PX1 Research has announced the launch of a new line of US-manufactured sublingual peptide strips designed for needle-free research applications. The product line includes formulations of Retatrutide, Tirzepatide, and BPC-157, marking a notable shift in how researchers can access these compounds. By moving away from traditional injectable formats, the company aims to provide a non-invasive oral delivery method that aligns with domestic quality control standards.
The strips are produced in the United States under current Good Manufacturing Practice (cGMP) protocols, ensuring rigorous quality control throughout the manufacturing process. Each batch undergoes High-Performance Liquid Chromatography (HPLC) purity verification, with results confirming 99% or greater purity across all formulations. Additionally, each product is accompanied by a Certificate of Analysis, giving researchers documented evidence of the batch composition before use. This emphasis on domestic manufacturing reflects a broader commitment to supply chain transparency, which is critical for researchers who require detailed documentation trails for institutional projects.
Among the available formulations, dissolving Retatrutide strips have drawn particular attention due to the compound's role in ongoing metabolic and weight regulation research. Tirzepatide and BPC-157 are also included, extending the lineup to cover compounds associated with glucose regulation and tissue repair research, respectively. The sublingual delivery format allows the strip to dissolve under the tongue, enabling absorption without the use of needles or syringes. This is especially beneficial in research environments where non-invasive administration methods are required, whether due to protocol specifications, institutional review considerations, or participant-facing study designs. The format addresses a logistical gap that injectable peptide formats cannot.
PX1 Research has positioned these sublingual peptide strips specifically for academic and institutional research contexts. They are not intended for clinical, therapeutic, or human consumption use. Instead, the product meets the demand from researchers who need compounds in a format compatible with non-invasive study designs, where traditional needle-based administration could introduce procedural variables or ethical complications. The inclusion of BPC-157 alongside GLP-1 receptor agonist-class compounds like Retatrutide and Tirzepatide signals that the line is designed to serve a range of research disciplines. Each compound has distinct molecular properties, and the sublingual strip format has been adapted to accommodate the specific stability and absorption characteristics relevant to each formulation.
The full product line is accessible through PX1 Research, with specific information on dissolving Retatrutide strips available directly on the product page. PX1 Research is a US-based supplier of research-grade peptide formulations manufactured under cGMP standards. The company provides sublingual peptide strips and related compounds, each accompanied by HPLC purity verification and a Certificate of Analysis, for use in academic and institutional research settings. For more information, visit PX1 Research.
